HBI Deals+Insights / News
The first FDA approval for an Alzheimer's drug in 20 years, aducanumab, sent the share price of South African and European hospital/imaging group Life Healthcare soaring 17%. The group manufacturers one of only three amyloid tracers for PET-CT diagnosis of the disease and is also the largest for-profit provider of PET-CT scans in Europe.